India Pharma Outlook Team | Wednesday, 01 April 2026
Rusan Healthcare has announced the launch of the APOSAN 3ml Pen, a multi-dose delivery pen device designed for better treatment in Parkinson’s disease ON-OFF episodes.
This new addition strengthens the company’s growing portfolio in Apomorphine Hydrochloride treatment, offering more flexible and patient-friendly options.
The APOSAN 3ml Pen uses a dial-a-dose system with a clear visibility window, helping patients deliver accurate doses with ease. Built for convenience, the lightweight, portable device supports safe self-administration at home, reducing handling complexity and lowering the risk of dosing errors. This marks a significant step in improving day-to-day Parkinson’s disease management.
Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies
Back in 2018, Rusan Pharma became the first in India to introduce APOSAN Apomorphine injections in 2ml and 5ml ampoules. Since then, the therapy has shown strong clinical outcomes and positive patient feedback, proving its value as a reliable option for managing sudden motor fluctuations.
With the new launch, the company now offers a complete range of Apomorphine Hydrochloride solutions, including 2ml injections, the APOSAN 3ml Pen, and 5ml formulations for infusion pumps. These options cater to different clinical needs, from rapid relief during OFF episodes to continuous symptom control.
Globally, Parkinson’s disease affects around 10 to 11.7 million people, with India contributing a rising share. Notably, Early Onset Parkinson’s Disease (EOPD) cases are increasing, with incidence rates tripling between 1990 and 2021.
The APOSAN 3ml Pen stands out as a practical innovation, helping patients regain control with faster, safer treatment access.
.jpg)
.jpg)
